Clinical Trials Browser

balstilimab × Sarcoma × Clear all

NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT05864534 2026-05-13

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Phase 2 Recruiting

25 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04028063 2026-04-20

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Phase 2 Active not recruiting

65 enrolled

Sarcoma

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Phase 1 Active not recruiting

499 enrolled

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Phase 2 Withdrawn

Sarcoma

Hemangiosarcoma